NAD(+) hydrolase SARM1 (NADase SARM1) (hSARM1) (EC 3.2.2.6) (NADP(+) hydrolase SARM1) (EC 3.2.2.-) (Sterile alpha and Armadillo repeat protein) (Sterile alpha and TIR motif-containing protein 1) (Sterile alpha motif domain-containing protein 2) (MyD88-5) (SAM domain-containing protein 2) (Tir-1 homolog) (HsTIR)
1_MVLTL 6_ LLSAY 11_ KLCRF 16_ FAMSG 21_ PRPGA 26_ ERLAV 31_ PGPDG 36_ GGGTG 41_ PWWAA 46_ GGRGP 51_ REVSP 56_ GAGTE 61_ VQDAL 66_ ERALP 71_ ELQQA 76_ LSALK 81_ QAGGA 86_ RAVGA 91_ GLAEV 96_ FQLVE 101_ EAWLL 106_ PAVGR 111_ EVAQG 116_ LCDAI 121_ RLDGG 126_ LDLLL 131_ RLLQA 136_ PELET 141_ RVQAA 146_ RLLEQ 151_ ILVAE 156_ NRDRV 161_ ARIGL 166_ GVILN 171_ LAKER 176_ EPVEL 181_ ARSVA 186_ GILEH 191_ MFKHS 196_ EETCQ 201_ RLVAA 206_ GGLDA 211_ VLYWC 216_ RRTDP 221_ ALLRH 226_ CALAL 231_ GNCAL 236_ HGGQA 241_ VQRRM 246_ VEKRA 251_ AEWLF 256_ PLAFS 261_ KEDEL 266_ LRLHA 271_ CLAVA 276_ VLATN 281_ KEVER 286_ EVERS 291_ GTLAL 296_ VEPLV 301_ ASLDP 306_ GRFAR 311_ CLVDA 316_ SDTSQ 321_ GRGPD 326_ DLQRL 331_ VPLLD 336_ SNRLE 341_ AQCIG 346_ AFYLC 351_ AEAAI 356_ KSLQG 361_ KTKVF 366_ SDIGA 371_ IQSLK 376_ RLVSY 381_ STNGT 386_ KSALA 391_ KRALR 396_ LLGEE 401_ VPRPI 406_ LPSVP 411_ SWKEA 416_ EVQTW 421_ LQQIG 426_ FSKYC 431_ ESFRE 436_ QQVDG 441_ DLLLR 446_ LTEEE 451_ LQTDL 456_ GMKSG 461_ ITRKR 466_ FFREL 471_ TELKT 476_ FANYS 481_ TCDRS 486_ NLADW 491_ LGSLD 496_ PRFRQ 501_ YTYGL 506_ VSCGL 511_ DRSLL 516_ HRVSE 521_ QQLLE 526_ DCGIH 531_ LGVHR 536_ ARILT 541_ AAREM 546_ LHSPL 551_ PCTGG 556_ KPSGD 561_ TPDVF 566_ ISYRR 571_ NSGSQ 576_ LASLL 581_ KVHLQ 586_ LHGFS 591_ VFIDV 596_ EKLEA 601_ GKFED 606_ KLIQS 611_ VMGAR 616_ NFVLV 621_ LSPGA 626_ LDKCM 631_ QDHDC 636_ KDWVH 641_ KEIVT 646_ ALSCG 651_ KNIVP 656_ IIDGF 661_ EWPEP 666_ QVLPE 671_ DMQAV 676_ LTFNG 681_ IKWSH 686_ EYQEA 691_ TIEKI 696_ IRFLQ 701_ GRSSR 706_ DSSAG 711_ SDTSL 716_EGAAP
1: NAD(+) hydrolase, which plays a key role in axonal degeneration following injury by regulating NAD(+) metabolism (PubMed:25908823, PubMed:27671644, PubMed:28334607). Acts as a negative regulator of MYD88- and TRIF-dependent toll-like receptor signaling pathway by promoting Wallerian degeneration, an injury-induced form of programmed subcellular death which involves degeneration of an axon distal to the injury site (PubMed:15123841, PubMed:16964262, PubMed:20306472, PubMed:25908823). Wallerian degeneration is triggered by NAD(+) depletion: in response to injury, SARM1 is activated and catalyzes cleavage of NAD(+) into ADP-D-ribose (ADPR), cyclic ADPR (cADPR) and nicotinamide; NAD(+) cleavage promoting cytoskeletal degradation and axon destruction (PubMed:25908823, PubMed:28334607, PubMed:30333228, PubMed:31128467, PubMed:31439792, PubMed:31439793, PubMed:32049506, PubMed:32828421, PubMed:33053563). Also able to hydrolyze NADP(+), but not other NAD(+)-related molecules (PubMed:29395922). Can activate neuronal cell death in response to stress (PubMed:20306472). Regulates dendritic arborization through the MAPK4-JNK pathway (By similarity). Involved in innate immune response: inhibits both TICAM1/TRIF- and MYD88-dependent activation of JUN/AP-1, TRIF-dependent activation of NF-kappa-B and IRF3, and the phosphorylation of MAPK14/p38 (PubMed:16964262)